The offer received bids for 80.52 lakh shares as against 1.44 crore shares on offer.
The initial public offer (IPO) of Krishna Institute of Medical Sciences received bids for 80.52 lakh shares as against 1.44 crore shares on offer, according to the stock exchange data at 17:00 IST on Thursday (17 June 2021). The issue was subscribed 0.56 times.
The issue opened for bidding on Wednesday, 16 June 2021, and it will close on Friday, 18 June 2021. The price band for the IPO is set at Rs 815-825 per share. An investor can bid for a minimum of 18 equity shares and in multiples thereof.
The IPO comprises fresh issue of shares aggregating up to Rs 200 crore and an offer for sale of up to 2,35,60,538 equity shares from promoters and existing shareholders.
Ahead of the IPO, the company finalized allocation of 1,15,84,060 equity shares to anchor investors at Rs 825 per share aggregating to Rs 955.68 crore.
The company proposes to utilize the net proceeds of the fresh issue towards repayment/pre-payment, in full or part, of certain borrowings availed by the company and by subsidiaries viz KHKPL (KIMS Hospital Kurnool), SIMSPL (Saveera Institute of Medical Science) and KHEPL (KIMS Hospital Enterprises) amounting Rs 150 crore and balance towards general corporate purposes.
Total borrowing as on 31 March 2020, was at Rs 220.164 crore.
Krishna Institute of Medical Sciences (KIMS) is one of the largest corporate healthcare groups in Andhra Pradesh (AP) and Telangana in terms of number of patients treated and treatments offered. It provides multi-disciplinary integrated healthcare services, with a focus on primary, secondary & tertiary care in tier 2-3 cities and primary, secondary, tertiary, and quaternary healthcare in tier 1 cities.
The company operates 9 multi-specialty hospitals under the KIMS Hospitals brand, with an aggregate bed capacity of 3,064, including over 2,500 operational beds as of March 31, 2021, which is 2.2 times more beds than the second largest provider in AP and Telangana. It offers a comprehensive range of healthcare services across over 25 specialties and super specialties, including cardiac sciences, oncology, neurosciences, gastric sciences, orthopaedics, organ transplantation, renal sciences and mother & childcare.
The company reported a consolidated net profit of Rs 201.22 crore and total income of Rs 1329.94 crore in the twelve months ended on 31 March 2021.
Powered by Capital Market - Live News
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)
Dear Reader,
Business Standard has always strived hard to provide up-to-date information and commentary on developments that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering have only made our resolve and commitment to these ideals stronger. Even during these difficult times arising out of Covid-19, we continue to remain committed to keeping you informed and updated with credible news, authoritative views and incisive commentary on topical issues of relevance.
We, however, have a request.
As we battle the economic impact of the pandemic, we need your support even more, so that we can continue to offer you more quality content. Our subscription model has seen an encouraging response from many of you, who have subscribed to our online content. More subscription to our online content can only help us achieve the goals of offering you even better and more relevant content. We believe in free, fair and credible journalism. Your support through more subscriptions can help us practise the journalism to which we are committed.
Support quality journalism and subscribe to Business Standard.
Digital Editor
RECOMMENDED FOR YOU